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ABSTRACT
Purpose: Oncology immunity was reported to play a key role in cancer 
development and progression, so we investigated the prediction role of several 
immune markers in esophageal squamous cell carcinoma (ESCC) patients after 
operation in this study.
Patients and Methods: 66 primary ESCC tumor tissues and four sets of tissue 
microarrays including 705 primary ESCC tumor tissues from four centers were 
collected and analyzed. Expressions of several immune markers in ESCC tumor tissue 
were detected with immunohistochemistry staining. Their distribution densities were 
analyzed with InForm™ 2.0.1 software. All statistic analyses were performed with 
SPSS16.0 and Stata version 10.0.
Results: Survival analyses assessed by Kaplan-Meier plots and log-rank tests 
demonstrated that densities of CD68 and interleukin 13 (IL-13) in tumor stroma 
were positively correlated with the overall survival of ESCC patients after operation 
(p < 0.01 for CD68, p < 0.001 for IL-13). Further, a model based on tumor stroma 
densities of CD68 and IL-13 was constructed and it could significantly classify 
patients with poor or good prognosis. This model could further identify high-risk 
group and low-risk group at the same Tumor lymph Nodes Metastases (TNM) stage. 
Lastly, a more accuracy model based on TNM stage, densities of CD68 and IL-13 was 
constructed to predict the prognosis of ESCC patient after operation.
Conclusion: Combining the TNM staging system and densities of CD68 and IL-13 
could substantially improve the prognosis prediction accuracy of ESCC patient after 
operation, which might be an excellent tool for selecting patients for individualized 
therapy in future.
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INTRODUCTION
It is estimated that there were 482,300 new 
esophageal squamous cell carcinoma (ESCC) cases and 
406,800 deaths in 2008 worldwide [1]. ESCC incidence 
varies as high as 16-fold in different areas [1]. Current 
Tumor lymph Nodes Metastases (TNM) staging system 
provides a useful benchmark for ESCC prognosis estimation 
and treatment strategy establishment. This system, however, 
is only based on the anatomical extent (tumor, lymph node 
and distant metastasis), histopathology type, biological 
activity and tumor location, which does not include the 
immune state of patient [2]. The role of immune system 
in cancer development and progression has been well 
established both in mice model [3,4] and on clinic [5, 6]. 
ESCC was not excluded from this dogma. Many immune 
cells and their related factors had been reported to be 
involved in the progression of it [7–9]. It is highly possible 
that the immune status of ESCC patient may provide useful 
information for the prognosis prediction, which may help to 
explain the discrepancy prognosis at the same TNM stage. 
Rapid progress of immunology unveils plenty 
of immune specific markers, which aids to the 
prompt detection of patient’s immune status with 
Figure 1: Representative images of different immune markers’ distribution in ESCC tissues detected with IHC 
staining. Lines of different color represented diverse areas of esophagus tissue. Positive stained cells were demonstrated as brown. 
Oncotarget15527www.impactjournals.com/oncotarget
immunohistochemistry (IHC) staining [10, 11]. We 
screened the expression and distribution of a panel of 
immune markers in ESCC primary tumor samples firstly, 
and found that the distribution of CD68 and interleukin 13 
(IL-13) could distinguish between good and poor prognosis. 
We then constructed a model based on these two immune 
markers to predict ESCC patients’ prognosis, which was 
further validated with samples from three external centers. 
This model could also classify high risk and low risk group 
even at the same TNM stage. A model based on TNM 
stage, densities of CD68 and IL-13 was further constructed 
to predict the prognosis of ESCC patient after operation.
RESULTS 
Distribution features of different immune 
markers in ESCC tumor area and adjacent area
Distribution features of CD1A, CD123, CD57, 
CD66b, CD68 and IL-13 were detected in 20 ESCC 
patients’ tumor tissues with IHC staining. Results 
demonstrated that they distributed differently in diversity 
areas (Figure 1). CD1A positive cells mainly distributed in 
tumor and normal stroma around the normal epithelium. 
CD123 positive cells mainly distributed in tumor stroma 
and normal stroma. CD57 and CD66b positive cells 
mainly existed in normal stroma and tumor stroma as well 
as in tumor area sometimes. CD68 and IL-13 positive 
cells distributed exclusively but with different densities 
in different areas. Higher magnification demonstrated the 
cellular location of respective marker was also provided 
(Supplementary Figures 1–6). From results of preliminary 
experiments, we observed that positive cells of CD1A, 
CD68 or IL-13 had distinct distribution among ESCC 
patients with good or poor prognosis.
Densities of CD68 and IL-13 positive cells in 
tumor stroma correlated to the survival time of 
ESCC patient after operation
Distribution densities of CD1A, IL-13 and CD68 in 
tumor stroma of 66 ESCC patients were further calculated 
with InForm™ 2.0.1 software (Figure 2). Results 
demonstrated that densities of CD68 and IL-13 in tumor 
stroma area were probably associated with the prognosis 
of patients. So the correlation between density of CD68 as 
well as IL-13 in tumor stroma and patients’ survival time 
was further confirmed by a TMA containing 194 ESCC 
tumor samples from the same center (training set). ROC 
curves analyses showed the optimum cutoff value for 
density of CD68 was 87 (CD68 density ≥ 87 was defined 
as CD68high group, CD68 density <87 was defined as 
CD68low group) and IL-13 was 23 (IL-23 density ≥ 23 was 
defined as IL-13high group, IL-23 density < 23 was defined 
as IL-13low group) respectively. Survival analyses assessed 
by Kaplan-Meier plots and log-rank tests disclosed that 
densities of both CD68 and IL-13 in tumor stroma were 
significantly positively correlated to the overall survival 
time and disease-free survival time of patients after 
operation (p < 0.0001, Figure 3A).
Figure 2: Diagrammatic sketch of immune markers’ distribution density in different areas processed by InForm™ 
2.0.1 software. The upper row presented original images that represented two different expression patterns (low density and high density) 
of CD68, IL-13 and CD1A. The middle row demonstrated segment maps, which divided tissues into tumor area (red) and tumor stroma area 
(green) processed by InForm™ 2.0.1 software. In bottom row, the nucleus of tumor cells or tumor stroma cells are marked in blue, Positive 
stained cells in tumor or tumor stroma were marked in brown.
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Model based on the tumor stroma densities of 
CD68 and IL-13 demonstrated priority at the 
prognosis prediction after operation
Univariate and multivariate Cox regression analysis 
were performed to explore whether CD68 and IL-13 were 
independent prognostic factors for ESCC patient or not 
(Table 1). The result demonstrated that tumor stroma 
densities of CD68 and IL-13 were independent prognostic 
factors for patients’ overall survival (p < 0.01). To explore 
whether they had more accuracy prognostic function when 
combined, we derived a model to calculate the union 
score for every patient with the densities of them and their 
weighted regression coefficient.
Union score = Density of CD68 * 0.711 + Density 
of IL-13 * 0.632
ROC curves analyses displayed that the optimum 
cutoff value for union score was 78, which divided 
patients (n = 194) into Unionhigh group (union score 
≥ 78) and Unionlow group (union score < 78) Pearson chi-
square test showed that clinicopathological characteristics 
did not vary significantly between the high-risk and low-
risk group (Table 2). Further, the relation of protective 
score and survival status was analyzed and the result 
demonstrated that patients with higher union score 
generally had longer survival time than those with lower 
score (Figure 3A). 5-year overall survival was 66% (95% 
CI 60.9–91.1) for the low-risk group, and 20% (95% CI 
19.9–20.4) for the high-risk group respectively (HR 0.358, 
95% CI 0.249–0.514).
Prognosis prediction of CD68 and IL-13 based 
model was validated from other three centers
Another 511 ESCC patients tumor tissues from 
three different centers including Northern and Southern 
areas of China (validation sets) (Table 2) were collected 
to confirm whether CD68 and IL-13 based model had 
popular prognostic priority in patients from different 
areas or not. As only overall survival data were collected 
in these 511 cases, we analyzed only the overall survival 
prognosis for them (Table 3). Kaplan-Meier analysis 
indicated that CD68 or IL-13 or union score with high 
value was associated with good prognosis and long overall 
survival time (Figure 3B). We observed similar relation 
of protective scores and survival status in the training set 
(HR 0.358, 95% CI 0.249–0.514; p < 0.0001; Table 3), 
as well as in three independent validation sets: validation 
set 1 (HR 0.247, 95% CI 0.160–0.382; p < 0.0001; 
Table 3), validation set2 (HR 0.186, 95% CI 0.112–0.308; 
p < 0.0001; Table 3) and validation set 3 (HR 0.206, 95% 
CI 0.085–0.498; p < 0.0001; Table 3). 
CD68 and IL-13 based model was superior to 
TNM staging system at prognosis prediction in 
these 705 ESCC patients
Next we compared the prediction accuracy 
of the two-immune marker-based model with other 
clinicopathological risk factors and single immune marker 
with ROC curves analyses. The result revealed that CD68 
and IL-13 density based union model demonstrated 
significantly higher prognostic accuracy than indicated 
clinicopathological factors including TNM staging in 
these 705 ESCC patients (Figure 4). In the analyses, 
TNM staging including TNM stage I, II, III and IV was 
considered as ordinal variable. Gender including male and 
female was considered as nominal variable. Age including 
age ≥ 60 and age < 60 was considered as nominal variable. 
Location, which meant ESCC located in upper chest, 
middle chest or low chest, was considered as nominal 
variable. Grade, which meant degree of differentiation 
including poor-differentiated, moderately differentiated, 
well-differentiated, was considered as ordinal variable.
CD68 and IL-13 based model could further 
identify high risk and low risk population at the 
same TNM stage
We also found that ESCC patient in advanced TNM 
stage had relatively low tumor stroma IL-13 density and 
low union score (Figure 5A). Further, we explored the 
prediction ability of CD68, IL-13 and union model at 
different TNM stages. Results demonstrated that CD68 
and IL-13 density based model could further identify 
low-risk group and high-risk group at every TNM stage 
(Figure 5B). Tumor stroma CD68 density could only 
identify low-risk group and high-risk group at TNM stage 
I, II and III (Figure 5B). Tumor stroma IL-13 density 
could only identify low-risk group and high-risk group at 
TNM stage II and III (Figure 5B).
Model combining TNM stage, CD68 and IL-13 
predicted more accuracy than any others
As CD68 density, IL-13 density and TNM stage 
were proved to be independent prediction factors 
for ESCC prognosis evaluated by multivariate cox 
regression analysis in all cases (n = 705) (Table 4), we 
further explored whether we could make more accuracy 
prediction or not by combining them. A formula based on 
the TNM stage, tumor stroma CD68 density, IL-13 density 
and their respective weighted regression coefficient was 
further constructed:
United score = Density of CD68 * 0.003 + Density 
of IL + 13 * 0.013 – TNM stage * 0.682
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Figure 3: Prognosis prediction of CD68, IL-13 and union model in ESCC patients. (A) Kaplan-Meier analysis demonstrated 
that high density of CD68 or IL-13 or union had good overall survival and disease-free survival for ESCC patient from Sun Yat-Sen 
University cancer center (training set). (B) Kaplan-Meier analysis validated that high density of CD68 or IL-13 or union had good overall 
survival for ESCC patients from three external centers. Validation set 1, The First Affiliated Hospital, Sun Yat-sen University; validation 
set 2, Linzhou Cancer Hospital (Henan, China); validation set 3, Hong Kong University.
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Table 1: Univariate and multivariate cox regression analysis for training set from SunYat-sen 
university cancer center
Variable
Univariate Multivariate
DFS OS DFS OS
P value P value HR (95% CI) P value HR (95% CI) P value
Gender 0.500 0.053
Age 0.596 0.904
Location 0.349 0.438
Grade 0.054 0.082
TNMstage 0.014 < 0.001 1.417 (0.985–2.037) 0.060 1.640 (1.172–2.295) < 0.001
CD68 0.010 < 0.001 0.597 (0.388–0.917) 0.018 0.457 (0.307–0.681) < 0.001
IL-13 0.039 < 0.001 0.670 (0.438–1.025) 0.065 0.376 (0.250–0.567) 0.004
In this comparison, TNM staging including TNM stage I, II, III and IV was considered as ordinal variable; Gender 
including male and female as nominal variable; Age including age ≥ 60 and age < 60 was considered as nominal variable; 
Location, which meant ESCC located in upper chest, middle chest or low chest, was considered as nominal variable; Grade, 
which meant degree of differentiation including poor-differentiated, moderately differentiated or well-differentiated, was 
considered as ordinal variable.
Table 2: Clinicopathological characteristics of ESCC patients from different centers
Clinical 
features
Training set Validation set 1 Validation set 2 Validation set 3
Case High (%) Low (%) Case High (%) Low (%) Case High (%) Low (%) Case High (%) Low (%)
Age (years old)
< 60
≥ 60
127
67
68 (53.5%)
38 (56.7%)
59 (46.5%)
29 (43.3%)
90
66
65 (72.2%)
46 (70.0%)
25 (28.0%)
20 (30.0%)
137
119
84 (61.3%)
74 (62.2%)
53 (38.7%)
45 (37.8%)
26
53
19 (73.1%)
43 (81.1%)
7 (26.9%)
10 
(18.9%)
Gender 
Male
Female
106
88
74 (69.8%)
64 (72.7%)
32 (30.2%)
24 (27.3%)
110
46
74 (67.3%)
26 (56.5%)
36 (32.7%)
20 (43.5%)
152
121
106 (69.7%)
88 (72.7%)
46 (30.3%)
33 (27.3%)
62
17
49 (79.0%)
13 (76.5%)
13 
(21.0%)
4 (23.5%)
Location
Upper
Middle
Lower
15
141
38
9 (60.0%)
79 (56.0%)
18 (47.4%)
6 (40.4%)
62 (44.0%)
20 (52.6%)
53
171
20
41 (77.4%)
97 (56.7%)
13 (65.0%)
12 (22.6%)
74 (43.3%)
7 (35.0%)
Differentiation
Grade 1
Grade 2
Grade 3
17
131
46
3 (17.6%)
71 (54.2%)
32 (69.6%)
14 (82.4%)
60 (45.8%)
14 (30.4%)
28
74
39
23 (82.1%)
45 (60.8%)
27 (69.2%)
5 (17.9%)
29 (39.2%)
12 (30.8%)
23
164
64
15 (65.2%)
94 (57.3%)
44 (68.8%)
8 (34.8%)
70 (42.7%)
20 (31.2%)
16
43
20
13 (81.2%)
32 (74.4%)
17 (78.5%)
3 (18.8%)
11 
(25.6%)
3 ( 21.5%)
pN category
N0
N1
104
90
51 (49.0%)
55 (61.1%)
53 (51.0%)
35 (38.9%)
106
50
63 (78.6%)
37 (61.3%)
43 (21.4%)
13 (38.7%)
151
105
93 (61.6%)
65 (61.9%)
58 (38.4%)
40 (38.1%)
29
50
24 (82.8%)
38 (76.0%)
5 (17.2%)
12 
(24.0%)
TNM stage
Early (I–II)
Advance 
(III–IV)
117
76
56 (47.9%)
49 (64.5%)
61 (52.1%)
27 (35.5%)
125
31
73 (58.4%)
27 (87.1%)
52 (41.6%)
4 (12.9%)
184
89
142 (56.3%)
52 (35.5%)
42 (43.6%)
37 (64.5%)
32
47
23 (71.9%)
39 (83.0%)
9 (28.1%)
8 (17.0%)
All 705 patients had undergone surgical resection and none of them received preoperative treatment. The median follow-
up was 23 months (IQR 13–36). Training set, Sun Yat-sen University Cancer Center; validation set 1, The First Affiliated 
Hospital, Sun Yat-sen University; validation set 2, Linzhou Cancer Hospital (Henan, China); validation set 3, Hong Kong 
university.
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The value of TNM stage was identified as following, 
TNM stage I as 1, TNM stage II as 2, TNM stage III as 
3, and TNM stage IV as 4. Patients were divided into 
Unitedlow group (United score < 0.82) and Unitedhigh 
(United score ≥ 0.82) group with the optimum cutoff value 
(0.82). Prediction result of united score in different centers 
was further analyzed with Kaplan-Meier analysis (Figure 
6A) as well as in all cases combined (Figure 6B). United 
score predicted more accuracy than TNM stage or CD68 
alone or IL-13alone or union score (Figure 6C).
Double staining of IL-13 with different immune 
markers 
Double staining of IL-13 with CD3, or CD56, or 
CD68, or CD20, or CD4 or CD8 was further performed 
to explore the source of IL-13 in ESCC patients. Results 
demonstrated that IL-13 could be expressed by CD3, CD4, 
CD8, CD56, CD68 and CD20 positive cell respectively in 
ESCC tumor tissue (Supplementary Figure 7).
DISCUSSION
Prognosis prediction played a critical role in the 
determination of therapy strategy for cancer patients. With 
the development of biology and new technique, many 
factors were reported to be correlated with the progression 
and prognosis of ESCC. [12–16] However, the TNM 
staging system is still the most popular accepted prognosis 
estimation for ESCC patients in clinical practice. Cancer 
is a system disease that plenty of elements were involved, 
so the ideal prognosis prediction model of which should 
Table 3: Univariate cox regression analysis of overall survival with different parameters in four 
centers
Training set Validation set 1 Validation set 2 Validation set 3
HR(95%CI) p value HR(95%CI) p value HR(95%CI) p value HR(95%CI) p value
Age 
(< 60* VS ≥ 60*)
1.286
(0.959–1.725)
0.093
1.025
(0.686–1.531)
0.904
4.995
(3.312–7.535)
< 0.001
1.93
(1.07–3.484)
0.029
Gender 
(male VS female)
0.881
(0.654–1.187)
0.406
0.612
(0.372–1.006)
0.053
0.899
(0.585–1.380)
0.626
0.482
(0.241–0.962)
0.039
Differentiation
(poor VS well)
1.344
(1.072–1.685)
0.01
1.355
(0.962–1.908)
0.082
1.004
(0.743–1.356)
0.981
0.994
(0.667–1.483)
0.978
Lymphatic metastasis
(yes VS no)
2.080
(1.548–2.795)
< 0.001
2.327
(1.579–3.427)
< 0.001
1.77
(1.196–2.620)
0.004
1.091
(0.629–1.892)
0.757
Distant metastasis
(yes VS no)
2.505
(1.025–6.118)
0.044
2.032
(1.186–3.482)
0.01
TNMstage
(advanced VS early)
2.306
(1.726–3.081)
< 0.001
2.423
(1.654–3.551)
< 0.001
2.002
(1.29–3.107)
0.002
1.547
(0.893–2.678)
0.12
CD68
(high VS low 
expression)
0.559
(0.412–0.758)
< 0.001
0.387
(0.261–0.574)
< 0.001
0.427
(0.284–0.642)
< 0.001
0.31
(0.16–0.602)
0.001
IL-13
(high VS low 
expression)
0.43
(0.315–0.588)
< 0.001
0.313
(0.211–0.464)
< 0.001
0.437
(0.292–0.654)
< 0.001
0.348
(0.186–0.654)
0.001
Union
(high VS low 
expression)
0.358
(0.249–0.514)
< 0.001
0.247
(0.16–0.382)
< 0.001
0.186
(0.112–0.308)
< 0.001
0.206
(0.085–0.498)
< 0.001
*Years old. Training set, Sun Yat-sen University Cancer Center; validation set 1, The First Affiliated Hospital, Sun Yat-sen 
University; validation set 2, Linzhou Cancer Hospital (Henan, China); validation set 3, Hong Kong university.
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be based on the integration analysis of all elements. It 
is inevitable to observe large variations in the clinical 
outcome of ESCC patient even with the same TNM stage, 
as the TNM staging system for ESCC mainly based on 
the anatomical extent (tumor, lymph node and distant 
metastasis), histopathologic type, biological activity and 
tumor location [2]. 
The immune system plays a key role in the 
progression of cancer. According to the description of 
Robert D. Schreiber et al., the correlation between immune 
system and cancer can be divided into three different 
phases [17]. In the full landscape of cancer development, 
the immune system played different roles. It could not 
only prevent the development of tumor by T cells, natural 
killer cells and natural killer T (NKT) cells secreted 
cytotoxic elements such as interferon-alpha (IFN-a), 
granzyme, perforin et al [18–22]. It could promote the 
progression of tumor by tumor associated macrophages, 
myeloid-derived suppressor cells and regulatory T cells 
[23, 24]. The immune system was ranked as the emerging 
hallmark for cancer, because of the important and diverse 
role it played in tumor progression [25]. So in this study, 
we investigated the prognosis value of different immune 
markers in ESCC patients. 
We systemically searched Pub Med for reports 
published before Feb 10, 2011 with the terms “esophageal 
squamous cell carcinoma”, “immune” and “prognosis”, 
and found that several immune markers were reported to be 
correlated with the prognosis of ESCC patients. While no 
systemically study was reported and evaluated from other 
Figure 4: CD68 and IL-13 based model displayed superior prognosis function compared with TNM staging system 
and other clinicopathological factors as well as single immune marker. ROC curves analyses of indicated elements in 705 
ESCC patients.
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Figure 5: CD68 and IL-13 based model could identify high risk and low risk population at the same TNM stage. 
(A) Tumor stroma CD68 density, IL-13 density and union model value at different TNM stages, *P < 0.05; **P < 0.01. (B) Prognosis 
prediction of CD68, IL-13 and union model at different TNM stages for ESCC patients.
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Table 4: Univariate and multivariate cox regression analysis for all cases
Clinical Features
Univariate analysis Multivariate analysis
HR (95% CI) P value HR (95% CI) P value
Gender 0.899 (0.585–1.380) 0.626
Age 1.004 (0.743–1.356) 0.981
Grade 0.994 (0.667–1.483) 0.978
TNMstage 2.020 (1.748–2.335) < 0.001 1.959 (1.683–2.281) < 0.001
CD68TS 0.449 (0.369–0.545) < 0.001 0.542 (0.444–0.662) < 0.001
IL-13TS 0.384 (0.316–0.468) < 0.001 0.456 (0.372–0.558) < 0.001
Figure 6: Prognosis prediction of united model compared with TNM stage, single immune marker and two-immune 
marker based model in survival function, sensitivity and specificity. (A) Kaplan-Meier analysis demonstrated that ESCC 
patients with high united score had good overall survival in four different centers. Training set, Sun Yat-sen University Cancer Center; 
validation set 1, The First Affiliated Hospital, Sun Yat-sen University; validation set 2, Linzhou Cancer Hospital (Henan, China); validation 
set 3, Hong Kong University. (B) Overall survival prediction function comparing of Union and United model in all cases. (C) ROC curves 
of indicated markers.
Oncotarget15535www.impactjournals.com/oncotarget
centers and applied to clinics. We planned to investigate 
the prognosis role of immune markers systemically and 
profoundly. So we began with investigating the expression 
and distribution of 21 different immune markers with 
different functions in tumor immunity to screen the 
possible correlation of their expressions with ESCC 
patients’ prognosis firstly. Six of them, as we reported in 
the manuscript, were selected for further study according 
to their expression characteristics after the first screen. 
We discovered that different immune markers distributed 
differently, even in the same patient, which might be 
correlated with the diversity of the immune system and the 
distinctive function of respective immune cell or cytokine. 
We further found that distribution densities of CD68 and 
IL-13 in tumor stroma area were positively correlated 
with ESCC patients’ overall survival after operation. 
CD68 was a popular marker for macrophages, which had 
been reported by plenty of investigations. The function 
of macrophages varied with local microenvironment and 
tumor characteristics. [25] For example, macrophages 
were reported to be associated with tumor progression and 
poor prognosis in breast cancer, [26] classic Hodgkin’s 
lymphoma, [27] and hepatocellular cancer, [28] et al. High 
macrophage density was also reported to be correlated 
with increased survival in non-small cell lung cancer [29]. 
We also found that patients with high density of tumor 
stroma CD68 positive cells had long overall survival in 
ESCC especially at TNM stage I, II and III. We also found 
that high density of IL-13 was a good prognostic factor for 
ESCC patients in this investigation. IL-13 was a cytokine 
which was first reported to be secreted by activated type 2 
T helper (Th2) cells, with the development of immunity, 
many innate immune cells were reported to can secrete 
IL-13 including eosinophils, basophils, mast cells, natural 
killer cells, NKT cells and group 2 innate lymphoid cells.
[30, 31] IL-13 was not only reported to play important role 
in helminthic parasites infection, allergic asthma, ulcerate 
colitis and eosinophilic esophagitis, [31, 32] which was 
reported to prevent tumor development and progression. 
For example, Low serum IL-13 concentration was reported 
to be correlated with poor prognosis of colorectal cancer, 
[33] and IL-13 had been reported to can protect mice 
from papilloma formation during 9,10-dimethyl-1,2-
benzanthracene/12-O-tetradecanoylphorbol-13-acetatetwo- 
step skin carcinogenesis via IL-4Rα induced signaling 
pathway. [34] In this investigation, IL-13 was found to be 
high expressed at the early stage of ESCC patient and high 
IL-13 density in tumor stroma predicted good prognosis, 
so IL-13 might also play similar protective role in ESCC 
progression.
Further, we developed a model based on densities 
of CD68 and IL-13, which was superior to the TNM stage 
system in the prognosis prediction of ESCC in the analyzed 
705 ESCC patients. It implied the important function of 
immune system in ESCC progression from another way. 
As TNM staging system was a comprehensive staging 
system, which had been evaluated by thousands of patients 
on clinic, the priority of CD68 and IL-13 based model 
to TNM staging system in ESCC prognosis prediction 
required further evaluation on clinic. The two immune 
markers based model could further identify high and low 
risk ESCC population even at the same TNM stage, which 
could provide more useful information for personalized 
therapy. So we further combined TNM stage and densities 
of CD68 and IL-13 in tumor stroma to construct a united 
model for ESCC prognosis prediction, which proved to 
can provide more accuracy prognosis prediction for ESCC 
patients after operation. As sample in our investigation 
was acquired from four different centers including ESCC 
high prevalence area such as Linzhou in North China 
as well as normal ESCC prevalence area as Guangzhou 
and Hong Kong in South China, the investigation could 
provide popular property for ESCC patients. 
MATERIALS AND METHODS
Specimen and sample
66 ESCC primary tumor specimens were applied 
for initial observation. Four sets of tissue microarrays 
(TMA) that contained formalin-fixed paraffin-embedded 
tumor tissues from 705 ESCC patients were performed 
in this study. TMA containing 194 primary ESCC 
tumor samples from Sun Yat-sen University cancer 
center (Guangzhou, China) was used as the training 
set, TMAs for validation were obtained from the First 
Affiliated Hospital, Sun Yat-sen University (Guangzhou, 
China, n = 156), Linzhou Cancer Hospital (Henan, China, 
n = 274) and Hong Kong University (Hong Kong, China, 
n = 81) respectively. None of these patients received 
preoperative treatment. Samples collected in this study 
were obtained under the approval of the Committees for 
Ethical Review of Research involving Human Subjects 
of Zhengzhou University, Sun Yat-sen University 
and Hong Kong University. TMA was constructed as 
described previously. [35]
IHC staining
Paraffin-embedded, formalin fixed tissues and TMA 
sections were deparaffinized and nonspecific bindings 
were blocked with 5% BSA in PBS for 30mins, RT. 
Tissues were then incubated with first antibody against 
human CD1A (Dako, Denmark ), or CD123 (Zhongshan 
Goldengridge, China), or CD57 (Zeta Cooperation, Sierra 
Madre, CA), or CD66b (Becton Dicknson, Bedford, MA) 
or CD68 (Abcam, UK), or IL-13 (Boster, China) at 4ºC 
overnight, and subsequently incubated with horseradish 
peroxidase (HRP)-conjugated second antibody (Dako, 
Denmark). Diaminobenzidine tetrahydrochloride (DAB) 
was used as the visualization substrate followed by counter 
Oncotarget15536www.impactjournals.com/oncotarget
staining with hematoxylin. Positively stained cells were 
counted with InForm™ 2.1software under microscope.
For double staining, formalin fixed ESCC tissues 
were deparaffinized and nonspecific bindings were 
blocked with 5% BSA in PBS for 30mins, RT. Tissues 
were then incubated with first antibody (rabbit origin) 
against human IL-13 and another first antibody (mouse 
origin) against human CD3 (Gene Tech Company, China), 
or CD4 (Gene Tech Company, China), or CD8 (Gene 
Tech Company, China ), or CD20 (Gene Tech Company, 
China ), or CD68, or CD56 (Gene Tech Company, China) 
at 4ºC overnight. Subsequently, tissues were incubated 
with mixer of HRP-conjugated goat anti-mouse IgG and 
alkaline phosphatase (AP)-conjugated goat anti-rabbit 
IgG (Golden Bridge International, USA). After washing, 
tissues were visualized with DAB and AP-red working 
solution. Hematoxylin was finally used to stain the 
nucleus.
Automatic image acquisition and analysis 
Vectra platform (Perkin-Elmer, Waltham, MA) was 
used for acquiring multispectral images (8bit). Nuance 
3.0 software (Perkin-Elmer, Waltham, MA) was then 
used to build distinctive spectral curves for both of the 
two chromogens (hematoxylin and DAB), then unmixed 
the signals of these images. In order to segregate tumor 
and stroma, 20% of these images were trained with 
InForm™ 2.0.1software (Perkin-Elmer, Waltham, MA). 
After training, area of tumor or stroma, numbers of tumor 
cell, stroma cell or positive stained cell in tumor area and 
stroma area were acquired with InForm™ 2.0.1software 
respectively. To calculate more reasonable and reliable, 
the distribution density of immune marker was calculated 
as 10^6*number of positive cells divided by area in pixel 
acquired with InForm™ 2.0.1 software.
Statistical analysis
All statistical analysis was performed with 
SPSS16.0 and Stata version 10.0 with two-tailed tests, 
and significance was defined as p values less than 0.05. 
The overall survival (OS) of each parameter was estimated 
with Kaplan-Meier method and long-rank test. The hazard 
ratio (HR) was calculated with multivariate Cox regression 
analysis. Receiver operating characteristics (ROC) curves 
were used to compare the sensitivity and specificity for 
the prediction of survival by immune markers and TNM 
stage. The relation between clinical characteristics and risk 
score model value was assessed with Student’s t test, or χ2 
Chi-Square test.
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